Compare BIO-TECHNE Corp (TECH) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Unilever plc — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Unilever plc trades at $62.45 (market cap $136.96B). The key difference: Unilever plc is far larger — about 12.1× BIO-TECHNE Corp's market cap, and Unilever plc pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| TECH | UL | |
|---|---|---|
Market Cap | $11.34B | $136.96B |
Sector | Health | Consumer Staples |
52-Week High | $72.48 | $74.59 |
52-Week Low | $43.31 | $55.05 |
Enterprise Value | $11.36B | $162.94B |
Dividend Yield | 0.44% | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Unilever (UL) trades at $63.54, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings misses contrast with strong profitability, including a net income margin of 18.32% and ROE of 54.57% for 2025. The company reported its strongest quarterly volume growth in over a decade in Q2 2026, raising its full-year outlook, while strategic shifts include focusing on beauty and personal care and a planned $65 billion merger with McCormick.
The outlook is mixed: robust fundamentals and strategic refocusing support long-term growth, particularly in emerging markets, but consistent earnings misses and a high P/E ratio of 21.46 pose valuation concerns. Risks include integration challenges from the McCormick deal and competitive pressures. Analyst consensus is divided, with 24% buy ratings, highlighting cautious optimism amid execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
